CRH (CRH) Q3 2024 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 TU earnings summary
8 Jul, 2026Executive summary
Delivered robust Q3 2024 results with 4% revenue growth to $10.5bn, 12% Adjusted EBITDA growth to $2.5bn, and 10% EPS growth, despite adverse weather and inflationary pressures.
Reaffirmed full-year guidance and positive outlook for 2025, supported by strong infrastructure and non-residential demand.
Significant portfolio activity with $4.6bn invested in 35 acquisitions, including major deals in Texas and Australia, and $1.2bn in divestitures year-to-date.
Ongoing share buyback program ($1.2bn YTD) and new $0.3bn tranche; quarterly dividend of $0.35/share (+5% annualized) declared.
CEO transition announced, with Albert Manifold retiring and Jim Mintern appointed as CEO.
Financial highlights
Q3 revenues reached $10.5bn (+4% YoY); 9M revenues at $26.7bn (+2%).
Q3 Adjusted EBITDA was $2.5bn (+12% YoY); 9M Adjusted EBITDA at $5.2bn (+12%).
Adjusted EBITDA margin expanded to 23.3% in Q3 (+170bps); 9M margin at 19.3% (+180bps).
Q3 EPS was $1.99 (+10% YoY); 9M EPS at $4.03 (+20% YoY).
Net income guidance for full year: $3.78–$3.85bn; EPS: $5.45–$5.55.
Outlook and guidance
Full-year Adjusted EBITDA expected between $6.87bn and $6.97bn, reaffirming guidance midpoint.
Capital expenditure guidance for 2024 raised to $2.4bn–$2.6bn.
Anticipates robust infrastructure demand in the U.S. and internationally, with gradual improvement in residential new-build activity in H2 2025 as interest rates normalize.
Positive pricing momentum and disciplined commercial management expected to continue.
Potential Q4 impairment in the range of $0.3–$0.4bn not reflected in current guidance.
Latest events from CRH
- Strong organic profit growth and cash generation cut year-end net debt below 3x EBITDA.CRH
H2 2015 - Strong growth and cash generation cut leverage to 1.7x while supporting further growth.CRH
H2 2016 - €3.3bn EBITDA, stronger margins and returns, and major acquisitions positioned for further growth.CRH
H2 2017 - U.S. momentum and cost actions supported 2013 progress as net debt fell EUR 519m.CRH
H2 2012 - H2 momentum improved as portfolio actions and disciplined investment set up a moderate 2014 recovery.CRH
H2 2013 - EBITDA rose 11% in 2014; 2015 priorities were growth, integration and debt reduction.CRH
H2 2014 - Sales rose 5% and EBITDA reached €1.66bn as margins proved resilient.CRH
H2 2011 - Cash discipline and cost savings steadied results as markets began to stabilize.CRH
H2 2010 - Q3 EBITDA held near prior year; FY26 guidance is $7.8B–$8.0B amid cost and residential headwinds.CRH
Q3 2026 - Q2 2026 saw strong growth, margin gains, and the Arcosa deal, supporting a positive outlook.CRH
Q2 2026